This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
Pfizer
Monte Rosa Therapeutics, Inc
Ipsen
Incyte Corporation
Immunitas Therapeutics
Nurix Therapeutics, Inc.
Arcus Biosciences, Inc.
Novartis
Shattuck Labs, Inc.
Ipsen
Seagen Inc.
Celldex Therapeutics
CytomX Therapeutics
NovalGen Ltd.
Eastern Cooperative Oncology Group
Seagen Inc.
AIDS Malignancy Consortium
Celgene
Opna Bio LLC
Novartis
Incyte Corporation
Pfizer
University of Wisconsin, Madison
Rennes University Hospital
Incyte Corporation
National Institutes of Health Clinical Center (CC)
European Organisation for Research and Treatment of Cancer - EORTC
Wake Forest University Health Sciences
Rutgers, The State University of New Jersey
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Scripps Health
Case Comprehensive Cancer Center